Search Results for "Abreva"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Abreva. Results 1 to 4 of 4 total matches.
See also: docosanol
Docosanol Cream (Abreva) for Recurrent Herpes Labialis
The Medical Letter on Drugs and Therapeutics • Nov 13, 2000 (Issue 1092)
Docosanol Cream (Abreva) for Recurrent Herpes Labialis ...
Doconsanol 10% cream, a long-chain saturated alcohol, has been approved by the FDA for over-the-counter treatment of herpes labialis.
Valacyclovir (Valtrex) for Oral Herpes
The Medical Letter on Drugs and Therapeutics • Nov 11, 2002 (Issue 1143)
% ointment (15g) 78.64
Docosanol
5
− Abreva (GlaxoSmithKline) 10% cream (2g) 5x/d until healed 13.75 ...
Valacyclovir (Valtrex - GlaxoSmithKline) was recently approved by the FDA for one-day oral treatment of patients at least 12 years old with orolabial herpes simplex infections. The drug was previously approved for treatment and suppression of genital herpes and for treatment of herpes zoster (shingles).
Antiviral Drugs for Varicella-Zoster Virus and Herpes Simplex Virus Infections
The Medical Letter on Drugs and Therapeutics • Sep 24, 2018 (Issue 1556)
as Denavir, docosanol
as Abreva, trifluridine ophthalmic solution as Viroptic, and ganciclovir ophthalmic ...
The recommendations for treatment of varicella-zoster
virus (VZV) and herpes simplex virus (HSV)
infections are listed in tables 1 and 2. Vaccination
against VZV was reviewed in a previous issue.
Antiviral Drugs
Treatment Guidelines from The Medical Letter • Mar 01, 2013 (Issue 127)
site and headache are common. Docosanol (Abreva)
cream started within 12 hours of prodromal symptoms ...
The drugs of choice for treatment of viral infections
(other than HIV) and their dosages are listed in Tables
1-6 on the pages that follow. Some of the indications
and dosages recommended here have not been
approved by the FDA. Vaccines used for the prevention
of viral infections are discussed elsewhere.